Press release
Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China
New patent expands composition of matter and use protection for COM902 beyond the United States and Europe HOLON, Israel, Nov. 2, 2020 /PRNewswire/ --
About this update from Compugen Ltd.
[{"type":"text","content":"New patent expands composition of matter and use protection for COM902 beyond the United States and Europe\n\n\nHOLON, Israel, Nov. 2, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of COM902, its immuno-oncology therapeutic antibody targeting TIGIT.\nChina Patent No. CN 110088132 B, titled \"Anti-TIGIT Antibodies, Anti-PVRIG Antibodies and Combinations Thereof,\" relates to the composition of matter of COM902, alone or in combination with a second antibody targeting an immune checkpoint, including PD-1 and PVRIG (specifically COM701). The patent further relates to the COM902 antibody composition for use in treating cancer by activating T cells. This patent is expected to expire no earlier than August 2037 in the China. \nThis first patent issued in China expands the intellectual property protection for COM902 beyond the United States and Europe where similar composition of matter and use patents have been granted. This patent, as well as other patents the Company is pursuing for COM902, are part of Compugen's global intellectual property and patent strategy across its innovative immuno-oncology pipeline.\nAbout COM902\nCOM902 is a high affinity, fully human antibody that blocks the interaction of TIGIT with PVR, its ligand, and consequently enhances T cell function. It is currently being evaluated in a Phase 1 clinical trial in patients with advanced malignancies who have exhausted all available standard therapies. Compugen has demonstrated in preclinical studies that simultaneous inhibition of TIGIT and PVRIG, the two coinhibitory arms of the DNAM axis, can increase antitumor immune responses, which may be further enhanced with the addition of PD-1 blockade. These data suggest that treatment with COM701 and COM902, targeting PVRIG and TIGIT, respectively, alone or in combination with a PD-1 inhibitor, has the potential to expand immuno-oncology treatment to patient populations who are non-responsive or refractory to existing immunotherapies. \nThe discovery of TIGIT, using the Company's computational discovery platform, was published by Compugen in October 2009 in the Proceedings o...